Welcome to our dedicated page for Mesa Laboratories news (Ticker: MLAB), a resource for investors and traders seeking the latest updates and insights on Mesa Laboratories stock.
Mesa Laboratories designs and manufactures life science tools and critical quality control solutions for regulated pharmaceutical, healthcare and medical device applications. The company reports through Sterilization and Disinfection Control, Biopharmaceutical Development, Calibration Solutions and Clinical Genomics, covering indicators for sterilization and cleaning processes, protein analysis and peptide synthesis systems, calibration products and genetic analysis tools.
Recurring company news includes quarterly and fiscal-year results, segment performance commentary, regular cash dividend declarations, investor conference participation and governance updates such as leadership transitions. Updates often connect Mesa's product mix, end-market conditions, debt management and operating margins with demand from regulated life sciences customers.
Mesa Laboratories, Inc. (NASDAQ:MLAB) reported a 29% revenue increase for Q4 2020, achieving $34,208, and a 14% rise for FY20, totaling $117,687. However, operating income fell 65% to $899 in Q4 and 23% to $7,494 for FY20. Net loss for Q4 was ($1,680), translating to a diluted loss per share of ($0.37). Excluding unusual items, adjusted operating income increased 32% in Q4. The Sterilization and Disinfection Control segment performed well, while Instruments and Continuous Monitoring faced declines due to COVID-19. Management anticipates ongoing challenges from the pandemic impacting sales.